Is it safe to combine caplyta (lumateperone) with AUVELITY (dextromethorphan/bupropion) and diazepam?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Combining Caplyta, AUVELITY, and Diazepam: Safety Considerations

This combination requires extreme caution and is generally not recommended due to significant risks of oversedation, respiratory depression, and CNS depression. The concurrent use of an atypical antipsychotic (lumateperone/Caplyta), an antidepressant combination containing bupropion (AUVELITY), and a benzodiazepine (diazepam) creates multiple concerning drug interactions.

Primary Safety Concerns

Critical Risk: CNS Depression with Benzodiazepine Combinations

The most serious concern is combining diazepam with either lumateperone or the dextromethorphan component of AUVELITY. Guidelines explicitly warn that combining benzodiazepines with antipsychotics carries risk of oversedation and respiratory depression, with fatalities reported when benzodiazepines are combined with high-dose olanzapine 1. While this specific warning references olanzapine, the mechanism applies broadly to atypical antipsychotics including lumateperone.

The 2019 Beers Criteria specifically identifies avoiding concurrent use of three or more CNS agents (including antidepressants, antipsychotics, and benzodiazepines) due to increased fall risk 2. This three-drug combination exceeds that threshold.

Seizure Risk with AUVELITY

AUVELITY contains bupropion, which lowers the seizure threshold and is contraindicated with recent benzodiazepine discontinuation 3. The FDA label explicitly states AUVELITY should not be used in patients who "have recently suddenly stopped...medicines called benzodiazepines" 3. While this refers to abrupt discontinuation rather than concurrent use, it highlights bupropion's interaction with GABAergic systems.

Importantly, AUVELITY is contraindicated in patients taking benzodiazepines who are at risk of abrupt discontinuation 3. The seizure risk with bupropion is dose-dependent, and AUVELITY contains 105 mg bupropion per dose 4, 5.

Additive Sedation and Respiratory Depression

Diazepam produces drowsiness and impairs vigilance 6. When combined with:

  • Lumateperone: The most common adverse effect is somnolence (12.5% vs 1.6% placebo) 7
  • AUVELITY's dextromethorphan component: Can cause CNS depression, though less pronounced than with benzodiazepines

The combination creates additive sedative effects with increased risk of respiratory depression, particularly in older or frail patients 1.

Specific Drug Interaction Analysis

Lumateperone (Caplyta) Considerations

Lumateperone is generally well-tolerated with minimal extrapyramidal symptoms and metabolic effects 8, 9, 7. However:

  • Primary adverse effects are somnolence (12.5%), dizziness (12.0%), and nausea (9.9%) 7
  • No specific contraindication with benzodiazepines in isolation, but general antipsychotic-benzodiazepine warnings apply 1

AUVELITY-Specific Warnings

The FDA label for AUVELITY explicitly warns about:

  • Alcohol and CNS depressants: "Advise patients that AUVELITY can increase adverse neuropsychiatric reactions or reduce alcohol tolerance" 3
  • Benzodiazepine interactions: Contraindicated with recent sudden benzodiazepine discontinuation 3
  • Multiple CNS medications: The combination of dextromethorphan and bupropion already affects multiple neurotransmitter systems 4, 5

Bupropion's interaction with diazepam has been studied: bupropion 100 mg actually abolished sedation from diazepam 2.5-5 mg in healthy volunteers 10. However, this does not eliminate respiratory depression risk, and higher doses or vulnerable populations may respond differently.

Clinical Decision Algorithm

If This Combination Is Already Prescribed:

  1. Immediate assessment required:

    • Evaluate for excessive sedation, respiratory depression, confusion
    • Check for falls, cognitive impairment, or paradoxical agitation
    • Monitor oxygen saturation if available
  2. Consider dose reduction or elimination:

    • First priority: Taper and discontinue diazepam if clinically feasible
    • Alternative: Use lowest effective doses with close monitoring
    • Avoid use in older adults (>65 years), those with COPD, or hepatic impairment 1
  3. If benzodiazepine is essential:

    • Use shortest-acting agent at lowest dose (e.g., lorazepam 0.25-0.5 mg PRN rather than standing diazepam) 1
    • Avoid scheduled dosing; use PRN only
    • Consider non-benzodiazepine alternatives for anxiety

If Considering This Combination:

Do not initiate this combination. Instead:

  1. For depression with bipolar features: Lumateperone monotherapy is FDA-approved and effective 8, 7

  2. For treatment-resistant depression: AUVELITY monotherapy shows rapid onset (within 1-2 weeks) 4, 5

  3. For anxiety requiring treatment:

    • Optimize antidepressant therapy first
    • Consider buspirone, hydroxyzine, or gabapentin as alternatives to benzodiazepines
    • If benzodiazepine absolutely necessary, use lowest dose PRN only
  4. Never combine all three agents without compelling clinical justification and intensive monitoring

Special Populations at Highest Risk

  • Older adults: Increased sensitivity to CNS depression, fall risk, and respiratory depression 1, 2, 1
  • COPD or respiratory disease: Benzodiazepine-antipsychotic combinations particularly dangerous 1
  • History of substance abuse: AUVELITY contains dextromethorphan (abuse potential) and bupropion 3
  • Seizure history: Absolute contraindication to AUVELITY 3

Monitoring If Combination Cannot Be Avoided

If clinical circumstances absolutely require this combination (which should be rare):

  • Respiratory monitoring: Pulse oximetry, especially during initiation
  • Fall precautions: Particularly first 2-4 weeks
  • Cognitive assessment: Monitor for confusion, delirium
  • Vital signs: Blood pressure (orthostatic hypotension risk with lumateperone)
  • Seizure precautions: Educate patient/family on seizure risk
  • Frequent follow-up: Weekly for first month, then biweekly

The safest approach is to avoid this combination entirely and use monotherapy or safer two-drug combinations with appropriate monitoring.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.